{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T21:33:57Z","timestamp":1795124037461,"version":"4.10.3"},"reference-count":120,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T00:00:00Z","timestamp":1671148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T00:00:00Z","timestamp":1671148800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100009010","name":"Novartis | Novartis Pharmaceuticals UK Limited","doi-asserted-by":"publisher","award":["OAP030A2401T"],"award-info":[{"award-number":["OAP030A2401T"]}],"id":[{"id":"10.13039\/100009010","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The aim of this systematic literature review is twofold, (1) detail the impact of retinal biomarkers identifiable via optical coherence tomography (OCT) on disease progression and response to treatment in neovascular age-related macular degeneration (nAMD) and (2) establish which biomarkers are currently identifiable by artificial intelligence (AI) models and the utilisation of this technology. Following the PRISMA guidelines, PubMed was searched for peer-reviewed publications dated between January 2016 and January 2022. Population: Patients diagnosed with nAMD with OCT imaging. Settings: Comparable settings to NHS hospitals. Study designs: Randomised controlled trials, prospective\/retrospective cohort studies and review articles. From 228 articles, 130 were full-text reviewed, 50 were removed for falling outside the scope of this review with 10 added from the author\u2019s inventory, resulting in the inclusion of 90 articles. From 9 biomarkers identified; intraretinal fluid (IRF), subretinal fluid, pigment epithelial detachment, subretinal hyperreflective material (SHRM), retinal pigmental epithelial (RPE) atrophy, drusen, outer retinal tabulation (ORT), hyperreflective foci (HF) and retinal thickness, 5 are considered pertinent to nAMD disease progression; IRF, SHRM, drusen, ORT and HF. A number of these biomarkers can be classified using current AI models. Significant retinal biomarkers pertinent to disease activity and progression in nAMD are identifiable via OCT; IRF being the most important in terms of the significant impact on visual outcome. Incorporating AI into ophthalmology practice is a promising advancement towards automated and reproducible analyses of OCT data with the ability to diagnose disease and predict future disease conversion.<\/jats:p>\n                  <jats:p>Systematic Review Registration: This review has been registered with PROSPERO (registration ID: CRD42021233200).<\/jats:p>","DOI":"10.1038\/s41433-022-02360-4","type":"journal-article","created":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T10:03:38Z","timestamp":1671185018000},"page":"2438-2453","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":66,"title":["Optical coherence tomography imaging biomarkers associated with neovascular age-related macular degeneration: a systematic review"],"prefix":"10.1038","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2569-9810","authenticated-orcid":false,"given":"Rachel L. W.","family":"Hanson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Archana","family":"Airody","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sobha","family":"Sivaprasad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard P.","family":"Gale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,16]]},"reference":[{"key":"2360_CR1","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1016\/S0140-6736(12)60282-7","volume":"379","author":"LS Lim","year":"2012","unstructured":"Lim LS, Mitchell P, Seddon JM, Holz FG, Wong TY. Age-related macular degeneration. Lancet. 2012;379:1728\u201338. https:\/\/doi.org\/10.1016\/S0140-6736(12)60282-7.","journal-title":"Lancet"},{"key":"2360_CR2","unstructured":"NICE. Age-related macular degener Age-related macular degeneration ation NICE guideline Y Your responsibility our responsibility. 2018 [cited 2018 Apr 18]; Available from: https:\/\/www.nice.org.uk\/guidance\/ng82\/resources\/agerelated-macular-degeneration-pdf-1837691334853."},{"key":"2360_CR3","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1136\/bjophthalmol-2014-306229","volume":"99","author":"AY Lee","year":"2015","unstructured":"Lee AY, Lee CS, Butt T, Xing W, Johnston RL, Chakravarthy U, et al. UK AMD EMR USERS GROUP REPORT V: Benefits of initiating ranibizumab therapy for neovascular AMD in eyes with vision better than 6\/12. Br J Ophthalmol. 2015;99:1045\u201350. http:\/\/group.bmj.com\/group\/rights-licensing\/permissions.","journal-title":"Br J Ophthalmol"},{"key":"2360_CR4","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1016\/j.ophtha.2012.04.015","volume":"119","author":"U Chakravarthy","year":"2012","unstructured":"Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, Wordsworth S, et al. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: One-year findings from the IVAN randomized trial. Ophthalmology. 2012;119:1399\u2013411.","journal-title":"Ophthalmology"},{"key":"2360_CR5","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1136\/bmj.c526","volume":"340","author":"U Chakravarthy","year":"2010","unstructured":"Chakravarthy U, Evans J, Rosenfeld PJ. Age related macular degeneration. BMJ. 2010;340:526\u201330.","journal-title":"BMJ."},{"key":"2360_CR6","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","volume":"119","author":"JS Heier","year":"2012","unstructured":"Heier JS, Brown DM, Chong V, Korobelnik JF, Kaiser PK, Nguyen QD, et al. Intravitreal aflibercept (VEGF Trap-Eye) in wet age-related macular degeneration. Ophthalmology 2012;119:2537\u201348.","journal-title":"Ophthalmology"},{"key":"2360_CR7","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1016\/j.ophtha.2012.03.053","volume":"119","author":"DF Martin","year":"2012","unstructured":"Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, Grunwald JE, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: Two-year results. Ophthalmology. 2012;119:1388\u201398. http:\/\/aaojournal.org.","journal-title":"Ophthalmology"},{"key":"2360_CR8","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1056\/NEJMoa1102673","volume":"364","author":"RG Catt","year":"2011","unstructured":"Catt RG, Martin DF, Maguire MG, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011;364:1897\u2013908.","journal-title":"N Engl J Med"},{"key":"2360_CR9","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1056\/NEJMoa054481","volume":"355","author":"PJ Rosenfeld","year":"2006","unstructured":"Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, et al. Ranibizumab for neovascular age-related macular degeneration. N. Engl J Med [Internet]. 2006;355:1419\u201331. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/17021318.","journal-title":"N. Engl J Med [Internet]"},{"key":"2360_CR10","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1056\/NEJMoa062655","volume":"355","author":"DM Brown","year":"2006","unstructured":"Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355:1432\u201344. http:\/\/www.nejm.org\/doi\/abs\/10.1056\/NEJMoa062655.","journal-title":"N Engl J Med"},{"key":"2360_CR11","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1007\/s00417-016-3353-7","volume":"254","author":"JH Kim","year":"2016","unstructured":"Kim JH, Lee DW, Chang YS, Kim JW, Kim CG. Twelve-month outcomes of treatment using ranibizumab or aflibercept for neovascular age-related macular degeneration: a comparative study. Graefe\u2019s Arch Clin Exp Ophthalmol. 2016;254:2101\u20139. https:\/\/doi.org\/10.1007\/s00417-016-3353-7.","journal-title":"Graefe\u2019s Arch Clin Exp Ophthalmol"},{"key":"2360_CR12","doi-asserted-by":"publisher","first-page":"e511","DOI":"10.1111\/aos.12618","volume":"93","author":"A Airody","year":"2015","unstructured":"Airody A, Venugopal D, Allgar V, Gale RP. Clinical characteristics and outcomes after 5 years pro re nata treatment of neovascular age-related macular degeneration with ranibizumab. Acta Ophthalmol. 2015;93:e511\u20132.","journal-title":"Acta Ophthalmol"},{"key":"2360_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.preteyeres.2015.07.007","volume":"50","author":"U Schmidt-Erfurth","year":"2016","unstructured":"Schmidt-Erfurth U, Waldstein SM. A paradigm shift in imaging biomarkers in neovascular age-related macular degeneration. Prog Retin Eye Res. 2016;50:1\u201324. https:\/\/doi.org\/10.1016\/j.preteyeres.2015.07.007.","journal-title":"Prog Retin Eye Res"},{"issue":"Suppl 2","key":"2360_CR14","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1136\/bjophthalmol-2014-305305","volume":"98","author":"G Trichonas","year":"2014","unstructured":"Trichonas G, Kaiser PK. Optical coherence tomography imaging of macular oedema. Br J Ophthalmol. 2014;98 Suppl 2:24\u20139.","journal-title":"Br J Ophthalmol"},{"key":"2360_CR15","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1136\/bjophthalmol-2014-305702","volume":"98","author":"U Schmidt-Erfurth","year":"2014","unstructured":"Schmidt-Erfurth U, Chong V, Loewenstein A, Larsen M, Souied E, Schlingemann R, et al. Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA). Br J Ophthalmol. 2014;98:1144\u201367.","journal-title":"Br J Ophthalmol"},{"key":"2360_CR16","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1097\/IAE.0000000000002670","volume":"40","author":"FG Holz","year":"2020","unstructured":"Holz FG, Figueroa MS, Bandello F, Yang Y, Ohji M, Dai H, et al. Ranibizumab treatment in treatment-naive neovascular age-related macular degeneration: results from luminous, a Global Real-World Study. Retina. 2020;40:1673\u201385.","journal-title":"Retina."},{"key":"2360_CR17","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1136\/bjophthalmol-2014-305327","volume":"99","author":"FG Holz","year":"2015","unstructured":"Holz FG, Tadayoni R, Beatty S, Berger A, Cereda MG, Cortez R, et al. Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration. Br J Ophthalmol. 2015;99:220\u20136.","journal-title":"Br J Ophthalmol"},{"key":"2360_CR18","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1177\/2474126417725946","volume":"1","author":"D Brown","year":"2017","unstructured":"Brown D, Heier JS, Boyer DS, Freund KB, Kaiser P, Kim JE, et al. Current best clinical practices\u2014management of neovascular AMD. J Vitreoretin Dis. 2017;1:294\u20137.","journal-title":"J Vitreoretin Dis"},{"key":"2360_CR19","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1016\/j.ophtha.2021.07.025","volume":"128","author":"S Sivaprasad","year":"2021","unstructured":"Sivaprasad S, Banister K, Azuro-Blanco A, Goulao B, Cook JA, Hogg R, et al. Diagnostic accuracy of monitoring tests of fellow eyes in patients with unilateral neovascular age-related macular degeneration: early detection of neovascular age-related macular degeneration study. Ophthalmology. 2021;128:1736\u201347. https:\/\/doi.org\/10.1016\/j.ophtha.2021.07.025.","journal-title":"Ophthalmology"},{"key":"2360_CR20","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/j.ajo.2015.06.023","volume":"160","author":"JL Prenner","year":"2015","unstructured":"Prenner JL, Halperin LS, Rycroft C, Hogue S, Williams Liu Z, Seibert R. Disease burden in the treatment of age-related macular degeneration: findings from a time-and-motion study. Am J Ophthalmol. 2015;160:725\u201331.e1.","journal-title":"Am J Ophthalmol"},{"key":"2360_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/bmjopen-2017-018289","volume":"7","author":"W Hollingworth","year":"2017","unstructured":"Hollingworth W, Jones T, Reeves BC, Peto T. A longitudinal study to assess the frequency and cost of antivascular endothelial therapy, and inequalities in access, in England between 2005 and 2015. BMJ Open. 2017;7:1\u201310.","journal-title":"BMJ Open"},{"key":"2360_CR22","doi-asserted-by":"crossref","unstructured":"Pezzullo L, Streatfeild J, Simkiss P, Shickle D The economic impact of sight loss and blindness in the UK adult population. BMC Health Serv Res. 2018;18. Available from: www.deloitte.com\/au\/about.","DOI":"10.1186\/s12913-018-2836-0"},{"key":"2360_CR23","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1136\/bjophthalmol-2014-305327","volume":"99","author":"FG Holz","year":"2014","unstructured":"Holz FG, Tadayoni R, Beatty S, Berger A, Cereda MG, Cortez R, et al. Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration. Br J Ophthalmol. 2014;99:220\u20136. https:\/\/doi.org\/10.1136\/bjophthalmol-2014-305327.","journal-title":"Br J Ophthalmol"},{"key":"2360_CR24","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.preteyeres.2017.12.002","volume":"65","author":"H Mehta","year":"2018","unstructured":"Mehta H, Tufail A, Daien V, Lee AY, Nguyen V, Ozturk M, et al. Real-world outcomes in patients with neovascular age-related macular degeneration treated with intravitreal vascular endothelial growth factor inhibitors. Prog Retin Eye Res. 2018;65:127\u201346. https:\/\/doi.org\/10.1016\/j.preteyeres.2017.12.002.","journal-title":"Prog Retin Eye Res"},{"issue":"May","key":"2360_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.preteyeres.2018.07.004","volume":"67","author":"U Schmidt-Erfurth","year":"2018","unstructured":"Schmidt-Erfurth U, Sadeghipour A, Gerendas BS, Waldstein SM, Bogunovi\u0107 H. Artificial intelligence in retina. Prog Retin Eye Res. 2018;67(May):1\u201329. https:\/\/doi.org\/10.1016\/j.preteyeres.2018.07.004.","journal-title":"Prog Retin Eye Res"},{"key":"2360_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13643-021-01626-4","volume":"10","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Syst Rev. 2021;10:1\u201311.","journal-title":"Syst Rev"},{"key":"2360_CR27","unstructured":"Silver Spring (MD): Food and Drug Administration (US); Bethesda (MD): National Institutes of Health (US). FDA-NIH Biomarker Working Group. BEST (Biomarkers, EndpointS, and other Tools) Resource.BEST (Biomarkers, EndpointS, and other Tools) Resource [Internet]. BEST (Biomarkers, EndpointS, and other Tools) Resource. Food and Drug Administration (US); 2016 [cited 2021 Dec 2]. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK326791\/."},{"key":"2360_CR28","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.1038\/s41433-020-0799-y","volume":"34","author":"U Chakravarthy","year":"2020","unstructured":"Chakravarthy U, Pillai N, Syntosi A, Barclay L, Best C, Sagkriotis A. Association between visual acuity, lesion activity markers and retreatment decisions in neovascular age-related macular degeneration. Eye. 2020;34:2249\u201356. https:\/\/doi.org\/10.1038\/s41433-020-0799-y.","journal-title":"Eye"},{"key":"2360_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-018-36704-6","volume":"9","author":"TT Lai","year":"2019","unstructured":"Lai TT, Hsieh YT, Yang CM, Ho TC, Yang CH. Biomarkers of optical coherence tomography in evaluating the treatment outcomes of neovascular age-related macular degeneration: a real-world study. Sci Rep. 2019;9:1\u201310.","journal-title":"Sci Rep."},{"key":"2360_CR30","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.4103\/ijo.IJO_3156_20","volume":"69","author":"D Alex","year":"2021","unstructured":"Alex D, Giridhar A, Gopalakrishnan M, Indurkhya S, Madan S. Subretinal hyperreflective material morphology in neovascular age-related macular degeneration: A case control study. Indian J Ophthalmol. 2021;69:1862\u20136. https:\/\/journals.lww.com\/ijo\/Fulltext\/2021\/07000\/Subretinal_hyperreflective_material_morphology_in.48.aspx.","journal-title":"Indian J Ophthalmol"},{"key":"2360_CR31","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1007\/s10384-018-0605-6","volume":"62","author":"M Ogasawara","year":"2018","unstructured":"Ogasawara M, Koizumi H, Yamamoto A, Itagaki K, Saito M, Maruko I, et al. Prognostic factors after aflibercept therapy for typical age-related macular degeneration and polypoidal choroidal vasculopathy. Jpn J Ophthalmol. 2018;62:584\u201391. https:\/\/doi.org\/10.1007\/s10384-018-0605-6.","journal-title":"Jpn J Ophthalmol"},{"key":"2360_CR32","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1097\/IAE.0000000000001748","volume":"38","author":"R Pokroy","year":"2018","unstructured":"Pokroy R, Mimouni M, Barayev E, Segev F, Geffen N, Nemet AY, et al. Prognostic value of subretinal hyperreflective material in neovascular age-related macular degeneration treated with bevacizumab. Retina. 2018;38:1485\u201391.","journal-title":"Retina."},{"key":"2360_CR33","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1016\/j.ophtha.2016.05.002","volume":"123","author":"I Chatziralli","year":"2016","unstructured":"Chatziralli I, Nicholson L, Vrizidou E, Koutsiouki C, Menon D, Sergentanis TN, et al. Predictors of outcome in patients with neovascular age-related macular degeneration switched from ranibizumab to 8-weekly aflibercept. Ophthalmol [Internet]. 2016;123:1762\u201370. https:\/\/doi.org\/10.1016\/j.ophtha.2016.05.002.","journal-title":"Ophthalmol [Internet]"},{"key":"2360_CR34","doi-asserted-by":"publisher","unstructured":"Zhang X, Lai TYY Baseline predictors of visual acuity outcome in patients with wet age-related macular degeneration. Biomed Res Int. 2018;2018. Available from: https:\/\/doi.org\/10.1155\/2018\/9640131.","DOI":"10.1155\/2018\/9640131"},{"key":"2360_CR35","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1167\/iovs.16-20637","volume":"58","author":"H Lee","year":"2017","unstructured":"Lee H, Jo A, Kim HC. Three-dimensional analysis of morphologic changes and visual outcomes in neovascular age-related macular degeneration. Investig Ophthalmol Vis Sci. 2017;58:1337\u201345.","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"2360_CR36","doi-asserted-by":"publisher","first-page":"e283","DOI":"10.1111\/aos.13880","volume":"97","author":"SHM van Romunde","year":"2019","unstructured":"van Romunde SHM, Polito A, Peroglio Deiro A, Bertazzi L, Guerriero M, Pertile G. Morphological changes in the diseased retina on a healthy choroid-retinal pigment epithelial complex after full macular translocation for exudative age-related macular degeneration. Acta Ophthalmol. 2019;97:e283\u20139.","journal-title":"Acta Ophthalmol"},{"key":"2360_CR37","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.ophtha.2015.09.013","volume":"123","author":"SM Waldstein","year":"2016","unstructured":"Waldstein SM, Wright J, Warburton J, Margaron P, Simader C, Schmidt-Erfurth U. Predictive value of retinal morphology for visual acuity outcomes of different ranibizumab treatment regimens for neovascular AMD. Ophthalmology. 2016;123:60\u20139.","journal-title":"Ophthalmology."},{"key":"2360_CR38","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1016\/j.ophtha.2016.03.037","volume":"123","author":"SM Waldstein","year":"2016","unstructured":"Waldstein SM, Simader C, Staurenghi G, Chong NV, Mitchell P, Jaffe GJ, et al. Morphology and visual acuity in aflibercept and ranibizumab therapy for neovascular age-related macular degeneration in the VIEW trials. Ophthalmology. 2016;123:1521\u20139.","journal-title":"Ophthalmology."},{"key":"2360_CR39","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1097\/IAE.0000000000001059","volume":"36","author":"NS Abdelfattah","year":"2016","unstructured":"Abdelfattah NS, Zhang H, Boyer DS, Sadda SR. Progression of macular atrophy in patients with neovascular age-related macular degeneration undergoing antivascular endothelial growth factor therapy. Retina. 2016;36:1843\u201350.","journal-title":"Retina."},{"key":"2360_CR40","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1001\/jamaophthalmol.2015.4948","volume":"134","author":"SM Waldstein","year":"2016","unstructured":"Waldstein SM, Philip AM, Leitner R, Simader C, Langs G, Gerendas BS, et al. Correlation of 3-dimensionally quantified intraretinal and subretinal fluid with visual acuity in neovascular age-related macular degeneration. JAMA Ophthalmol. 2016;134:182\u201390.","journal-title":"JAMA Ophthalmol"},{"key":"2360_CR41","doi-asserted-by":"publisher","first-page":"2157","DOI":"10.1007\/s00417-017-3776-9","volume":"255","author":"EC Kang","year":"2017","unstructured":"Kang EC, Choi S, Koh HJ. Inner nuclear layer cystoid spaces are a poor prognostic factor in typical age-related macular degeneration and polypoidal choroidal vasculopathy. Graefe\u2019s Arch Clin Exp Ophthalmol. 2017;255:2157\u201363.","journal-title":"Graefe\u2019s Arch Clin Exp Ophthalmol"},{"key":"2360_CR42","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.ophtha.2018.08.035","volume":"126","author":"GJ Jaffe","year":"2019","unstructured":"Jaffe GJ, Ying GS, Toth CA, Daniel E, Grunwald JE, Martin DF, et al. Macular morphology and visual acuity in year five of the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2019;126:252\u201360.","journal-title":"Ophthalmology."},{"key":"2360_CR43","doi-asserted-by":"publisher","first-page":"OCT288","DOI":"10.1167\/iovs.15-18753","volume":"57","author":"G Casalino","year":"2016","unstructured":"Casalino G, Bandello F, Chakravarthy U. Changes in neovascular lesion hyperreflectivity after anti-VEGF treatment in age-related macular degeneration: An integrated multimodal imaging analysis. Investig Ophthalmol Vis Sci. 2016;57:OCT288\u201398.","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"2360_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-021-86348-2","volume":"11","author":"C Tuerksever","year":"2021","unstructured":"Tuerksever C, Pruente C, Hatz K. High frequency SD-OCT follow-up leading to up to biweekly intravitreal ranibizumab treatment in neovascular age-related macular degeneration. Sci Rep. 2021;11:1\u201310. https:\/\/doi.org\/10.1038\/s41598-021-86348-2.","journal-title":"Sci Rep."},{"key":"2360_CR45","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1136\/bjophthalmol-2018-313447","volume":"104","author":"T Lin","year":"2020","unstructured":"Lin T, Dans KC, Muftuoglu IK, Meshi A, Amador-Patarroyo MJ, Cheng L, et al. Factors associated with extended remission in neovascular age-related macular degeneration on pro re nata treatment protocol. Br J Ophthalmol. 2020;104:58\u201363. https:\/\/bjo.bmj.com\/content\/bjophthalmol\/early\/2019\/07\/13\/bjophthalmol-2018-313447.full.pdf.","journal-title":"Br J Ophthalmol"},{"key":"2360_CR46","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1007\/s00417-020-04730-8","volume":"258","author":"L Marquis","year":"2020","unstructured":"Marquis L, Mantel I. Beneficial switch from aflibercept to ranibizumab for the treatment of refractory neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2020;258:1591\u20136. https:\/\/doi.org\/10.1007\/s00417-020-04730-8.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"2360_CR47","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1097\/IAE.0000000000000690","volume":"36","author":"O Segal","year":"2016","unstructured":"Segal O, Barayev E, Nemet AY, Mimouni M. Predicting response of exudative age-related macular degeneration to Bevacizumab based on spectralis optical coherence tomography. Retina. 2016;36:259\u201363.","journal-title":"Retina."},{"key":"2360_CR48","doi-asserted-by":"publisher","first-page":"2983","DOI":"10.1038\/s41433-020-01354-4","volume":"35","author":"U Chakravarthy","year":"2021","unstructured":"Chakravarthy U, Havilio M, Syntosi A, Pillai N, Wilkes E, Benyamini G, et al. Impact of macular fluid volume fluctuations on visual acuity during anti-VEGF therapy in eyes with nAMD. Eye. 2021;35:2983\u201390. https:\/\/doi.org\/10.1038\/s41433-020-01354-4.","journal-title":"Eye"},{"key":"2360_CR49","doi-asserted-by":"publisher","first-page":"240","DOI":"10.3341\/kjo.2016.0026","volume":"31","author":"JM Kim","year":"2017","unstructured":"Kim JM, Kim JH, Chang YS, Kim JW, Kim CG, Lee DW. Treatment of bilateral retinal angiomatous proliferation with anti-vascular endothelial growth factor: 12-month outcome. Korean J Ophthalmol. 2017;31:240.","journal-title":"Korean J Ophthalmol"},{"key":"2360_CR50","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1016\/j.ophtha.2020.03.010","volume":"127","author":"U Schmidt-Erfurth","year":"2020","unstructured":"Schmidt-Erfurth U, Vogl WD, Jampol LM, Bogunovi\u0107 H. Application of automated quantification of fluid volumes to Anti\u2013VEGF therapy of neovascular age-related macular degeneration. Ophthalmology. 2020;127:1211\u20139.","journal-title":"Ophthalmology."},{"key":"2360_CR51","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1097\/IAE.0000000000001494","volume":"37","author":"JH Kim","year":"2017","unstructured":"Kim JH, Chang YS, Kim JW. Natural course of patients discontinuing treatment for age-related macular degeneration and factors associated with visual prognosis. Retina. 2017;37:2254\u201361.","journal-title":"Retina."},{"key":"2360_CR52","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1111\/aos.13565","volume":"96","author":"M Ashraf","year":"2018","unstructured":"Ashraf M, Souka A, Adelman RA. Age-related macular degeneration: using morphological predictors to modify current treatment protocols. Acta Ophthalmol. 2018;96:120\u201333.","journal-title":"Acta Ophthalmol"},{"key":"2360_CR53","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.ophtha.2015.09.013","volume":"123","author":"SM Waldstein","year":"2016","unstructured":"Waldstein SM, Wright J, Warburton J, Margaron P, Simader C, Schmidt-Erfurth U. Predictive value of retinal morphology for visual acuity outcomes of different ranibizumab treatment regimens for neovascular AMD. Ophthalmology. 2016;123:60\u20139. https:\/\/doi.org\/10.1016\/j.ophtha.2015.09.013.","journal-title":"Ophthalmology"},{"key":"2360_CR54","doi-asserted-by":"crossref","unstructured":"Azar G, Wolff B, De Bats F, Halfon J, Streho M, Tick S, et al. Morphological Predictive Features on Spectral-Domain Optical Coherence Tomography for Visual Outcomes in Neovascular Age-Related Macular Degeneration Treated with Ranibizumab. Biomed Res Int. 2018;2018. Available from: Azar, G., Wolff, B., Bats, F. De, Halfon, J., Streho, M., Tick, S., Castelnovo, L., Michel, G., Masse, H., Vasseur, V., Sahyoun, M., & Mauget-fa\u00ffsse, M. (2018). Morphological Predictive Features on Spectral-Domain Optical Coherence Tomography for Visual O","DOI":"10.1155\/2018\/7438083"},{"key":"2360_CR55","unstructured":"Fragiotta S, Rossi T, Cutini A, Grenga PL, Vingolo EM Predictive factors for development of neovascular age-related macular degeneration: A Spectral-Domain Optical Coherence Tomography Study. Retina. 2017;1\u20138. Available from: http:\/\/www.scopus.com\/inward\/record.url?eid=2-s2.0-85011665459&partnerID=MN8TOARS."},{"key":"2360_CR56","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1111\/aos.13359","volume":"95","author":"CR Clemens","year":"2017","unstructured":"Clemens CR, Wolf A, Alten F, Milojcic C, Heiduschka P, Eter N. Response of vascular pigment epithelium detachment due to age-related macular degeneration to monthly treatment with ranibizumab: the prospective, multicentre RECOVER study. Acta Ophthalmol. 2017;95:683\u20139.","journal-title":"Acta Ophthalmol"},{"key":"2360_CR57","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.ajo.2016.03.039","volume":"166","author":"HJ Cho","year":"2016","unstructured":"Cho HJ, Kim KM, Kim HS, Lee DW, Kim CG, Kim JW. Response of pigment epithelial detachment to anti-vascular endothelial growth factor treatment in age-related macular degeneration. Am J Ophthalmol. 2016;166:112\u20139. https:\/\/doi.org\/10.1016\/j.ajo.2016.03.039.","journal-title":"Am J Ophthalmol"},{"key":"2360_CR58","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.4103\/ijo.IJO_2977_20","volume":"69","author":"AS Kelkar","year":"2021","unstructured":"Kelkar AS, Kelkar J, Bolisetty M, Kelkar SB. Original Article Visual outcomes, safety profile and morphometric response of optical coherence tomography biomarkers to ranibizumab biosimilar treatment in neovascular age\u2014related macular degeneration: Real\u2014world evidence. Indian J Ophthalmol. 2021;69:1469\u201374.","journal-title":"Indian J Ophthalmol."},{"key":"2360_CR59","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1080\/17469899.2020.1745062","volume":"15","author":"G Casalino","year":"2020","unstructured":"Casalino G, Scialdone A, Bandello F, Chakravarthy U. Hyperreflective material as a biomarker in neovascular age-related macular degeneration. Expert Rev Ophthalmol. 2020;15:83\u201391. https:\/\/doi.org\/10.1080\/17469899.2020.1745062.","journal-title":"Expert Rev Ophthalmol"},{"key":"2360_CR60","doi-asserted-by":"publisher","first-page":"3519","DOI":"10.1167\/iovs.17-21696","volume":"58","author":"D Ferrara","year":"2017","unstructured":"Ferrara D, Silver RE, Louzada RN, Novais EA, Collins GK, Seddon JM. Optical coherence tomography features preceding the onset of advanced age-related macular degeneration. Investig Ophthalmol Vis Sci. 2017;58:3519\u201329.","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"2360_CR61","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1167\/iovs.18-25189","volume":"60","author":"PK Roberts","year":"2019","unstructured":"Roberts PK, Zotter S, Montuoro A, Pircher M, Baumann B, Ritter M, et al. Identification and quantification of the angiofibrotic switch in neovascular AMD. Investig Ophthalmol Vis Sci. 2019;60:304\u201311. https:\/\/doi.org\/10.1167\/iovs.18-25189.","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"2360_CR62","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.ajo.2017.06.015","volume":"181","author":"Y Kawashima","year":"2017","unstructured":"Kawashima Y, Hata M, Oishi A, Ooto S, Yamashiro K, Tamura H, et al. Association of vascular versus avascular subretinal hyperreflective material with aflibercept response in age-related macular degeneration. Am J Ophthalmol. 2017;181:61\u201370. https:\/\/doi.org\/10.1016\/j.ajo.2017.06.015.","journal-title":"Am J Ophthalmol"},{"key":"2360_CR63","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1167\/iovs.15-18572","volume":"57","author":"NS Abdelfattah","year":"2016","unstructured":"Abdelfattah NS, Zhang H, Boyer DS, Rosenfeld PJ, Feuer WJ, Gregori G, et al. Drusen volume as a predictor of disease progression in patients with late age-related macular degeneration in the fellow eye. Investig Ophthalmol Vis Sci. 2016;57:1839\u201346.","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"2360_CR64","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1016\/j.ophtha.2019.05.016","volume":"126","author":"M Nassisi","year":"2019","unstructured":"Nassisi M, Lei J, Abdelfattah NS, Karamat A, Balasubramanian S, Fan W, et al. OCT risk factors for development of late age-related macular degeneration in the fellow eyes of patients enrolled in the HARBOR study. Ophthalmology. 2019;126:1667\u201374. https:\/\/doi.org\/10.1016\/j.ophtha.2019.05.016.","journal-title":"Ophthalmology"},{"key":"2360_CR65","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1159\/000505628","volume":"63","author":"A Lamin","year":"2020","unstructured":"Lamin A, El Nokrashy A, Chandra S, Sivaprasad S. Association of longitudinal changes in drusen characteristics and retinal layer volumes with subsequent subtype of choroidal neovascularisation. Ophthalmic Res. 2020;63:375\u201382.","journal-title":"Ophthalmic Res"},{"key":"2360_CR66","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.ophtha.2015.09.016","volume":"123","author":"FA Folgar","year":"2016","unstructured":"Folgar FA, Yuan EL, Sevilla MB, Chiu SJ, Farsiu S, Chew EY, et al. Drusen volume and retinal pigment epithelium abnormal thinning volume predict 2-year progression of age-related macular degeneration. Ophthalmology. 2016;123:39\u201350.e1.","journal-title":"Ophthalmology"},{"key":"2360_CR67","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1001\/jamaophthalmol.2020.1376","volume":"138","author":"SebastianMMDP Waldstein","year":"2020","unstructured":"Waldstein SebastianMMDP, Vogl W-DP, Bogunovic HP, Sadeghipour AP, Riedl SM, Schmidt-Erfurth UM. Characterization of drusen and hyperreflective foci as biomarkers for disease progression in age-related macular degeneration using artificial intelligence in optical coherence tomography. JAMA Ophthalmol. 2020;138:740\u20137. https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/fullarticle\/2765650?utm_campaign=articlePDF&utm_medium=articlePDFlink&utm_source=articlePDF&utm_content=jamaophthalmol.2020.1376.","journal-title":"JAMA Ophthalmol"},{"issue":"7 July","key":"2360_CR68","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0255213","volume":"16","author":"S Notomi","year":"2021","unstructured":"Notomi S, Shiose S, Ishikawa K, Fukuda Y, Kano K, Mori K, et al. Drusen and pigment abnormality predict the development of neovascular age-related macular degeneration in Japanese patients. PLoS One. 2021;16(7 July):1\u201311. https:\/\/doi.org\/10.1371\/journal.pone.0255213.","journal-title":"PLoS One"},{"key":"2360_CR69","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1016\/j.ophtha.2016.02.043","volume":"123","author":"Q Zhou","year":"2016","unstructured":"Zhou Q, Daniel E, Maguire MG, Grunwald JE, Martin ER, Martin DF, et al. Pseudodrusen and incidence of late age-related macular degeneration in fellow eyes in the comparison of age-related macular degeneration treatments trials. Ophthalmol [Internet]. 2016;123:1530\u201340. https:\/\/doi.org\/10.1016\/j.ophtha.2016.02.043.","journal-title":"Ophthalmol [Internet]"},{"key":"2360_CR70","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1007\/s00417-019-04373-4","volume":"257","author":"JH Kim","year":"2019","unstructured":"Kim JH, Kim JW, Kim CG, Lee DW. Focal retinal pigment epithelium atrophy at the location of type 3 neovascularization lesion: a morphologic feature associated with low reactivation rate and favorable prognosis. Graefe\u2019s Arch Clin Exp Ophthalmol. 2019;257:1661\u20139. https:\/\/doi.org\/10.1007\/s00417-019-04373-4.","journal-title":"Graefe\u2019s Arch Clin Exp Ophthalmol"},{"key":"2360_CR71","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.ophtha.2017.09.028","volume":"125","author":"SR Sadda","year":"2018","unstructured":"Sadda SR, Guymer R, Holz FG, Schmitz-Valckenberg S, Curcio CA, Bird AC, et al. Consensus definition for atrophy associated with age-related macular degeneration on OCT: classification of atrophy report 3. Ophthalmology. 2018;125:537\u201348. https:\/\/doi.org\/10.1016\/j.ophtha.2017.09.028.","journal-title":"Ophthalmology"},{"key":"2360_CR72","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1177\/1120672120908718","volume":"31","author":"MA Oliveira","year":"2021","unstructured":"Oliveira MA, Farinha C, Rodrigues TM, Martins A, Cachulo M, da L, et al. Macular atrophy development in neovascular age-related macular degeneration during first year of treatment: Incidence and risk factors. Eur J Ophthalmol. 2021;31:521\u20138.","journal-title":"Eur J Ophthalmol"},{"key":"2360_CR73","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.jcjo.2021.01.018","volume":"56","author":"AX Chen","year":"2021","unstructured":"Chen AX, Haueisen A, Rasendran C, Hom GL, Conti TF, Conti FF, et al. Visual outcomes following cataract surgery in age-related macular degeneration patients. Can J Ophthalmol. 2021;56:348\u201354. https:\/\/doi.org\/10.1016\/j.jcjo.2021.01.018.","journal-title":"Can J Ophthalmol"},{"key":"2360_CR74","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.oret.2019.09.016","volume":"4","author":"M Pfau","year":"2020","unstructured":"Pfau M, M\u00f6ller PT, K\u00fcnzel SH, Von Der Emde L, Lindner M, Thiele S, et al. Type 1 choroidal neovascularization is associated with reduced localized progression of atrophy in age-related macular degeneration. Ophthalmol Retin. 2020;4:238\u201348. https:\/\/doi.org\/10.1016\/j.oret.2019.09.016.","journal-title":"Ophthalmol Retin"},{"key":"2360_CR75","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s00508-020-01718-6","volume":"133","author":"C Ebner","year":"2021","unstructured":"Ebner C, Wernigg C, Sch\u00fctze C, Weingessel B, V\u00e9csei-Marlovits PV. Retinal pigment epithelial characteristics in eyes with neovascular age-related macular degeneration: Long-term retinal changes under anti-vascular endothelial growth factor treatment. Wien Klin Wochenschr. 2021;133:123\u201330.","journal-title":"Wien Klin Wochenschr"},{"key":"2360_CR76","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1016\/j.ajo.2015.02.020","volume":"159","author":"C Sch\u00fctze","year":"2015","unstructured":"Sch\u00fctze C, Wedl M, Baumann B, Pircher M, Hitzenberger CK, Schmidt-Erfurth U. Progression of retinal pigment epithelial atrophy in antiangiogenic therapy of neovascular age-related macular degeneration. Am J Ophthalmol. 2015;159:1100\u201314.e1.","journal-title":"Am J Ophthalmol"},{"key":"2360_CR77","doi-asserted-by":"publisher","first-page":"427","DOI":"10.4103\/0301-4738.187659","volume":"64","author":"M Kim","year":"2016","unstructured":"Kim M, Kim E, Seo K, Yu SY, Kwak HW. Change of retinal pigment epithelial atrophy after anti-vascular endothelial growth factor treatment in exudative age-related macular degeneration. Indian J Ophthalmol. 2016;64:427\u201333.","journal-title":"Indian J Ophthalmol"},{"key":"2360_CR78","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12886-018-0960-6","volume":"18","author":"A Kovacs","year":"2018","unstructured":"Kovacs A, Kiss T, Rarosi F, Somfai GM, Facsko A, Degi R. The effect of ranibizumab and aflibercept treatment on the prevalence of outer retinal tubulation and its influence on retreatment in neovascular age-related macular degeneration 11 Medical and Health Sciences 1113 Ophthalmology and Optometry. BMC Ophthalmol. 2018;18:1\u20136. https:\/\/doi.org\/10.1186\/s12886-018-0960-6.","journal-title":"BMC Ophthalmol"},{"key":"2360_CR79","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/j.ophtha.2008.12.039","volume":"116","author":"M Bolz","year":"2009","unstructured":"Bolz M, Schmidt-Erfurth U, Deak G, Mylonas G, Kriechbaum K, Scholda C. Optical coherence tomographic hyperreflective foci. a morphologic sign of lipid extravasation in diabetic macular edema. Ophthalmology. 2009;116:914\u201320. https:\/\/doi.org\/10.1016\/j.ophtha.2008.12.039.","journal-title":"Ophthalmology"},{"key":"2360_CR80","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1016\/j.ajo.2011.08.041","volume":"153","author":"A Uji","year":"2012","unstructured":"Uji A, Murakami T, Nishijima K, Akagi T, Horii T, Arakawa N, et al. Association between hyperreflective foci in the outer retina, status of photoreceptor layer, and visual acuity in diabetic macular edema. Am J Ophthalmol. 2012;153:710\u20137.e1. https:\/\/doi.org\/10.1016\/j.ajo.2011.08.041.","journal-title":"Am J Ophthalmol"},{"key":"2360_CR81","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1097\/IAE.0b013e318217ffc7","volume":"32","author":"K Ogino","year":"2012","unstructured":"Ogino K, Murakami T, Tsujikawa A, Miyamoto K, Sakamoto A, Ota M, et al. Characteristics of optical coherence tomographic hyperreflective foci in retinal vein occlusion. Retina. 2012;32:77\u201385.","journal-title":"Retina."},{"key":"2360_CR82","doi-asserted-by":"crossref","first-page":"BIO211","DOI":"10.1167\/iovs.16-19778","volume":"58","author":"CA Curcio","year":"2017","unstructured":"Curcio CA, Zanzottera EC, Ach T, Balaratnasingam C, Freund KB. Activated retinal pigment epithelium, an optical coherence tomography biomarker for progression in age-related macular degeneration. Invest Ophthalmol Vis Sci. 2017;58:BIO211\u201326.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"Suppl 1","key":"2360_CR83","doi-asserted-by":"publisher","first-page":"S12","DOI":"10.1097\/IAE.0000000000001276","volume":"36","author":"EC Zanzottera","year":"2016","unstructured":"Zanzottera EC, Ach T, Huisingh C, Messinger JD, Spaide RF, Curcio CA. Visualizing retinal pigment epithelium phenotypes in the transition to geographic atrophy in age-related macular degeneration. Retina 2016;36 Suppl 1:S12\u201325.","journal-title":"Retina"},{"key":"2360_CR84","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1136\/bjophthalmol-2016-308422","volume":"101","author":"FG Schlanitz","year":"2017","unstructured":"Schlanitz FG, Baumann B, Kundi M, Sacu S, Baratsits M, Scheschy U, et al. Drusen volume development over time and its relevance to the course of age-related macular degeneration. Br J Ophthalmol. 2017;101:198\u2013203.","journal-title":"Br J Ophthalmol"},{"key":"2360_CR85","doi-asserted-by":"publisher","first-page":"3431","DOI":"10.1167\/iovs.18-24143","volume":"59","author":"M Nassisi","year":"2018","unstructured":"Nassisi M, Fan W, Shi Y, Lei J, Borrelli E, Ip M, et al. Quantity of intraretinal hyperreflective foci in patients with intermediate age-related macular degeneration correlates with 1-year progression. Invest Ophthalmol Vis Sci. 2018;59:3431\u20139. http:\/\/rsb.info.nih.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2360_CR86","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s00417-019-04546-1","volume":"11","author":"Y Hsia","year":"2021","unstructured":"Hsia Y, Yang CH, Hsieh YT, Yang CM, Ho TC, Lai TT. Hyperreflective foci in predicting the treatment outcomes of diabetic macular oedema after anti-vascular endothelial growth factor therapy. Sci Rep. 2021;11:273\u201380. https:\/\/doi.org\/10.1007\/s00417-019-04546-1.","journal-title":"Sci Rep."},{"key":"2360_CR87","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1007\/s00508-015-0772-0","volume":"128","author":"B Weingessel","year":"2016","unstructured":"Weingessel B, Mihaltz K, V\u00e9csei-Marlovits PV. Predictors of 1-year visual outcome in OCT analysis comparing ranibizumab monotherapy versus combination therapy with PDT in exsudative age-related macular degeneration. Wien Klin Wochenschr. 2016;128:560\u20135.","journal-title":"Wien Klin Wochenschr"},{"key":"2360_CR88","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1136\/bjophthalmol-2018-312625","volume":"103","author":"JB Kumar","year":"2019","unstructured":"Kumar JB, Wai KM, Ehlers JP, Singh RP, Rachitskaya AV. Subfoveal choroidal thickness as a prognostic factor in exudative age-related macular degeneration. Br J Ophthalmol. 2019;103:918\u201321.","journal-title":"Br J Ophthalmol"},{"key":"2360_CR89","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1007\/s00417-017-3888-2","volume":"256","author":"W Fan","year":"2018","unstructured":"Fan W, Abdelfattah NS, Uji A, Lei J, Ip M, Sadda SVR, et al. Subfoveal choroidal thickness predicts macular atrophy in age-related macular degeneration: results from the TREX-AMD trial. Graefe\u2019s Arch Clin Exp Ophthalmol. 2018;256:511\u20138. https:\/\/doi.org\/10.1007\/s00417-017-3888-2.","journal-title":"Graefe\u2019s Arch Clin Exp Ophthalmol"},{"key":"2360_CR90","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1167\/tvst.9.2.1","volume":"9","author":"MA Zarbin","year":"2020","unstructured":"Zarbin MA. Artificial intelligence: quo vadis? Transl Vis Sci Technol. 2020;9:4\u20137.","journal-title":"Transl Vis Sci Technol"},{"key":"2360_CR91","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1038\/s41591-018-0107-6","volume":"24","author":"J De Fauw","year":"2018","unstructured":"De Fauw J, Ledsam JR, Romera-Paredes B, Nikolov S, Tomasev N, Blackwell S, et al. Clinically applicable deep learning for diagnosis and referral in retinal disease. Nat Med. 2018;24:1342\u201350.","journal-title":"Nat Med"},{"key":"2360_CR92","doi-asserted-by":"publisher","unstructured":"Arcadu F, Benmansour F, Maunz A, Willis J, Haskova Z, Prunotto M Deep learning algorithm predicts diabetic retinopathy progression in individual patients. npj Digit Med. 2019;2. Available from: https:\/\/doi.org\/10.1038\/s41746-019-0172-3.","DOI":"10.1038\/s41746-019-0172-3"},{"key":"2360_CR93","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.oret.2016.12.009","volume":"1","author":"CS Lee","year":"2017","unstructured":"Lee CS, Baughman DM, Lee AY. Deep learning is effective for classifying normal versus age-related macular degeneration OCT images. Kidney Int Rep. 2017;1:322\u20137. https:\/\/doi.org\/10.1016\/j.oret.2016.12.009.","journal-title":"Kidney Int Rep."},{"key":"2360_CR94","doi-asserted-by":"publisher","first-page":"3440","DOI":"10.1364\/BOE.8.003440","volume":"8","author":"CS Lee","year":"2017","unstructured":"Lee CS, Tyring AJ, Deruyter NP, Wu Y, Rokem A, Lee AY. Deep-learning based, automated segmentation of macular edema in optical coherence tomography. Biomed Opt Express. 2017;8:3440.","journal-title":"Biomed Opt Express"},{"key":"2360_CR95","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1001\/jama.2017.18152","volume":"318","author":"DSW Ting","year":"2017","unstructured":"Ting DSW, Cheung CYL, Lim G, Tan GSW, Quang ND, Gan A, et al. Development and validation of a deep learning system for diabetic retinopathy and related eye diseases using retinal images from multiethnic populations with diabetes. J Am Med Assoc. 2017;318:2211\u201323.","journal-title":"J Am Med Assoc"},{"key":"2360_CR96","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12886-020-01382-4","volume":"20","author":"T Tsuji","year":"2020","unstructured":"Tsuji T, Hirose Y, Fujimori K, Hirose T, Oyama A, Saikawa Y, et al. Classification of optical coherence tomography images using a capsule network. BMC Ophthalmol [Internet]. 2020;20:1\u20139. https:\/\/doi.org\/10.1186\/s12886-020-01382-4.","journal-title":"BMC Ophthalmol [Internet]"},{"key":"2360_CR97","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s11517-019-02066-y","volume":"58","author":"AM Alqudah","year":"2020","unstructured":"Alqudah AM. AOCT-NET: a convolutional network automated classification of multiclass retinal diseases using spectral-domain optical coherence tomography images. Med Biol Eng Comput. 2020;58:41\u201353. https:\/\/doi.org\/10.1007\/s11517-019-02066-y.","journal-title":"Med Biol Eng Comput"},{"key":"2360_CR98","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s00417-018-04224-8","volume":"257","author":"F Li","year":"2019","unstructured":"Li F, Chen H, Liu Z, Zhang X, Wu Z. Fully automated detection of retinal disorders by image-based deep learning. Graefe\u2019s Arch Clin Exp Ophthalmol. 2019;257:495\u2013505. https:\/\/doi.org\/10.1007\/s00417-018-04224-8.","journal-title":"Graefe\u2019s Arch Clin Exp Ophthalmol"},{"key":"2360_CR99","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1109\/TMI.2019.2919951","volume":"39","author":"P Seebock","year":"2020","unstructured":"Seebock P, Orlando JI, Schlegl T, Waldstein SM, Bogunovic H, Klimscha S, et al. Exploiting epistemic uncertainty of anatomy segmentation for anomaly detection in retinal OCT. IEEE Trans Med Imaging. 2020;39:87\u201398.","journal-title":"IEEE Trans Med Imaging"},{"key":"2360_CR100","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/s00417-017-3850-3","volume":"256","author":"M Treder","year":"2018","unstructured":"Treder M, Lauermann JL, Eter N. Automated detection of exudative age-related macular degeneration in spectral domain optical coherence tomography using deep learning. Graefe\u2019s Arch Clin Exp Ophthalmol. 2018;256:259\u201365. https:\/\/doi.org\/10.1007\/s00417-017-3850-3.","journal-title":"Graefe\u2019s Arch Clin Exp Ophthalmol"},{"key":"2360_CR101","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.ophtha.2017.10.031","volume":"125","author":"T Schlegl","year":"2018","unstructured":"Schlegl T, Waldstein SM, Bogunovic H, Endstra\u00dfer F, Sadeghipour A, Philip AM, et al. Fully automated detection and quantification of macular fluid in OCT using deep learning. Ophthalmology. 2018;125:549\u201358. https:\/\/doi.org\/10.1016\/j.ophtha.2017.10.031.","journal-title":"Ophthalmology"},{"key":"2360_CR102","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1016\/j.ophtha.2016.04.005","volume":"123","author":"U Chakravarthy","year":"2016","unstructured":"Chakravarthy U, Goldenberg D, Young G, Havilio M, Rafaeli O, Benyamini G, et al. Automated identification of lesion activity in neovascular age-related macular degeneration. Ophthalmology. 2016;123:1731\u20136. https:\/\/doi.org\/10.1016\/j.ophtha.2016.04.005.","journal-title":"Ophthalmology"},{"key":"2360_CR103","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.ophtha.2020.06.038","volume":"128","author":"TDL Keenan","year":"2021","unstructured":"Keenan TDL, Clemons TE, Domalpally A, Elman MJ, Havilio M, Agr\u00f3n E, et al. Retinal specialist versus artificial intelligence detection of retinal fluid from OCT: age-related eye disease study 2: 10-year follow-on study. Ophthalmology. 2021;128:100\u20139.","journal-title":"Ophthalmology"},{"key":"2360_CR104","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1007\/s10278-021-00459-w","volume":"34","author":"LB Sappa","year":"2021","unstructured":"Sappa LB, Okuwobi IP, Li M, Zhang Y, Xie S, Yuan S, et al. RetFluidNet: retinal fluid segmentation for SD-OCT images using convolutional neural network. J Digit Imaging. 2021;34:691\u2013704. https:\/\/doi.org\/10.1007\/s10278-021-00459-w.","journal-title":"J Digit Imaging"},{"key":"2360_CR105","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.oret.2017.03.015","volume":"2","author":"U Schmidt-Erfurth","year":"2018","unstructured":"Schmidt-Erfurth U, Bogunovic H, Sadeghipour A, Schlegl T, Langs G, Gerendas BS, et al. Machine learning to analyze the prognostic value of current imaging biomarkers in neovascular age-related macular degeneration. Ophthalmol Retin. 2018;2:24\u201330.","journal-title":"Ophthalmol Retin"},{"key":"2360_CR106","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.ajo.2017.10.015","volume":"185","author":"TM Aslam","year":"2018","unstructured":"Aslam TM, Zaki HR, Mahmood S, Ali ZC, Ahmad NA, Thorell MR, et al. Use of a neural net to model the impact of optical coherence tomography abnormalities on vision in age-related macular degeneration. Am J Ophthalmol. 2018;185:94\u2013100.","journal-title":"Am J Ophthalmol"},{"key":"2360_CR107","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.ajo.2020.12.012","volume":"224","author":"TDL Keenan","year":"2021","unstructured":"Keenan TDL, Chakravarthy U, Loewenstein A, Chew EY, Schmidt-Erfurth U. Automated quantitative assessment of retinal fluid volumes as important biomarkers in neovascular age-related macular degeneration. Am J Ophthalmol. 2021;224:267\u201381. https:\/\/doi.org\/10.1016\/j.ajo.2020.12.012.","journal-title":"Am J Ophthalmol"},{"key":"2360_CR108","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.oret.2021.12.007","volume":"6","author":"S Riedl","year":"2022","unstructured":"Riedl S, Vogl WD, Waldstein SM, Schmidt-Erfurth U, Bogunovi\u0107 H. Impact of intra- and subretinal fluid on vision based on volume quantification in the HARBOR trial. Ophthalmol Retin. 2022;6:291\u20137.","journal-title":"Ophthalmol Retin"},{"key":"2360_CR109","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1007\/s00417-018-4040-7","volume":"256","author":"C von der Burchard","year":"2018","unstructured":"von der Burchard C, Treumer F, Ehlken C, Koinzer S, Purtskhvanidze K, Tode J, et al. Retinal volume change is a reliable OCT biomarker for disease activity in neovascular AMD. Graefe\u2019s Arch Clin Exp Ophthalmol. 2018;256:1623\u20139. https:\/\/doi.org\/10.1007\/s00417-018-4040-7.","journal-title":"Graefe\u2019s Arch Clin Exp Ophthalmol"},{"key":"2360_CR110","doi-asserted-by":"publisher","first-page":"3240","DOI":"10.1167\/iovs.16-21053","volume":"58","author":"H Bogunovic","year":"2017","unstructured":"Bogunovic H, Waldstein SM, Schlegl T, Langs G, Sadeghipour A, Liu X, et al. Prediction of anti-VEGF treatment requirements in neovascular AMD using a machine learning approach. Invest Ophthalmol Vis Sci. 2017;58:3240\u20138.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2360_CR111","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1167\/tvst.10.7.30","volume":"10","author":"M Pfau","year":"2021","unstructured":"Pfau M, Sahu S, Rupnow RA, Romond K, Millet D, Holz FG, et al. Probabilistic forecasting of anti-vegf treatment frequency in neovascular age-related macular degeneration. Transl Vis Sci Technol. 2021;10:1\u201311.","journal-title":"Transl Vis Sci Technol"},{"key":"2360_CR112","doi-asserted-by":"publisher","first-page":"3261","DOI":"10.1007\/s00417-021-05247-4","volume":"259","author":"X Zhao","year":"2021","unstructured":"Zhao X, Zhang X, Lv B, Meng L, Zhang C, Liu Y, et al. Optical coherence tomography-based short-term effect prediction of anti-vascular endothelial growth factor treatment in neovascular age-related macular degeneration using sensitive structure guided network. Graefe\u2019s Arch Clin Exp Ophthalmol. 2021;259:3261\u20139.","journal-title":"Graefe\u2019s Arch Clin Exp Ophthalmol"},{"key":"2360_CR113","doi-asserted-by":"publisher","first-page":"3199","DOI":"10.1167\/iovs.18-24106","volume":"59","author":"U Schmidt-Erfurth","year":"2018","unstructured":"Schmidt-Erfurth U, Waldstein SM, Klimscha S, Sadeghipour A, Hu X, Gerendas BS, et al. Prediction of individual disease conversion in early AMD using artificial intelligence. Investig Ophthalmol Vis Sci. 2018;59:3199\u2013208.","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"2360_CR114","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-020-72359-y","volume":"10","author":"I Banerjee","year":"2020","unstructured":"Banerjee I, de Sisternes L, Hallak JA, Leng T, Osborne A, Rosenfeld PJ, et al. Prediction of age-related macular degeneration disease using a sequential deep learning approach on longitudinal SD-OCT imaging biomarkers. Sci Rep. 2020;10:1\u201316. https:\/\/doi.org\/10.1038\/s41598-020-72359-y.","journal-title":"Sci Rep."},{"key":"2360_CR115","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1038\/s41591-020-0867-7","volume":"26","author":"J Yim","year":"2020","unstructured":"Yim J, Chopra R, Spitz T, Winkens J, Obika A, Kelly C, et al. Predicting conversion to wet age-related macular degeneration using deep learning. Nat Med. 2020;26:892\u20139. https:\/\/doi.org\/10.1038\/s41591-020-0867-7.","journal-title":"Nat Med"},{"key":"2360_CR116","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1038\/s41433-019-0747-x","volume":"34","author":"AH Ross","year":"2020","unstructured":"Ross AH, Downey L, Devonport H, Gale RP, Kotagiri A, Mahmood S, et al. Recommendations by a UK expert panel on an a fl ibercept treat-and- extend pathway for the treatment of neovascular age-related macular degeneration. Eye. 2020;34:1825\u201334. https:\/\/doi.org\/10.1038\/s41433-019-0747-x.","journal-title":"Eye"},{"key":"2360_CR117","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1097\/IAE.0000000000002531","volume":"40","author":"X Hu","year":"2020","unstructured":"Hu X, Waldstein SM, Klimscha S, Sadeghipour A, Bogunovic H, Gerendas BS, et al. Morphological and functional characteristics at the onset of exudative conversion in age-related macular degeneration. Retina. 2020;40:1070\u20138. https:\/\/journals.lww.com\/retinajournal\/Fulltext\/2020\/06000\/MORPHOLOGICAL_AND_FUNCTIONAL_CHARACTERISTICS_AT.9.aspx.","journal-title":"Retina"},{"key":"2360_CR118","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.survophthal.2012.01.006","volume":"57","author":"PA Keane","year":"2012","unstructured":"Keane PA, Patel PJ, Liakopoulos S, Heussen FM, Sadda SR, Tufail A. Evaluation of age-related macular degeneration with optical coherence tomography. Surv Ophthalmol. 2012;57:389\u2013414.","journal-title":"Surv Ophthalmol"},{"key":"2360_CR119","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1111\/ceo.13837","volume":"48","author":"R Guymer","year":"2020","unstructured":"Guymer R, Wu Z. Age-related macular degeneration (AMD): More than meets the eye. The role of multimodal imaging in today\u2019s management of AMD\u2014A review. Clin Exp Ophthalmol. 2020;48:983\u201395.","journal-title":"Clin Exp Ophthalmol."},{"key":"2360_CR120","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1001\/archophthalmol.2009.326","volume":"127","author":"SA Zweifel","year":"2009","unstructured":"Zweifel SA, Engelbert M, Laud K, Margolis R, Spaide RF, Freund KB. Outer retinal tubulation a novel optical coherence tomography finding. Arch Ophthalmol. 2009;127:1596\u2013602.","journal-title":"Arch Ophthalmol"}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41433-022-02360-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-022-02360-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-022-02360-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,2]],"date-time":"2023-08-02T11:06:48Z","timestamp":1690974408000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41433-022-02360-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,16]]},"references-count":120,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["2360"],"URL":"https:\/\/doi.org\/10.1038\/s41433-022-02360-4","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,16]]},"assertion":[{"value":"7 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"RPG has received honorarium for advisory board meetings and speaker fees from Abbvie, Allergan, Alimera, Apellis, Bayer, Heidelberg Engineering, Lux Biosciences, Novartis, Notal Vision and Roche, and has been awarded institutional grants from Novartis Pharmaceuticals UK Ltd and Bayer Pharmaceuticals. SS has been awarded institutional research grants and received support for publication from Novartis, Bayer, Allergan\/Abbvie and Boehringer Ingleheim, S.S. also attended advisory board meetings of Allergan, Apellis, Bayer, Boehringer Ingelheim, Heidelberg Engineering, Novartis, Oxurion, Oculis, Optos, Ophthea, Roche.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}